Rexahn Pharmaceuticals Inc. (RNN) Company Profile


	The Wright Reports site is no longer hosted or operated by Manta. Please review the following: 1. You have been redirected to CorporateInformation.com where you can view Snapshot reports or purchase Wright reports or subscriptions of your choosing. 2. If you were previously linking to Wright Reports please change your links to www.corporateinformation.com 3. If you are a paid subscriber with an active subscription please continue on to the member site: http://member.corporateinformation.com/home.asp 4. For additional information related to CorporateInformation.com please contact help@corporateinformation.com, Contact phone nr to be provided later)

Rexahn Pharmaceuticals Inc. Company Snapshot

Business Description:

Rexahn Pharmaceuticals Inc. operates in the Pharmaceutical preparations sector. Rexahn Pharmaceuticals, Inc. (Rexahn) is a clinical stage biopharmaceutical company developing and seeking to deliver cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Rexahn's pipeline features three drug candidates in Phase II clinical trials and seven or more other drug candidates in pre-clinical development. Rexahn has three clinical stage drug candidates: Archexin, Serdaxin, and Zoraxel. Archexin, is a inhibitor of the protein kinase Akt. Archexin is developed for five cancer indications (renal cell carcinoma (RCC), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer). Its products in the pre-clinical pipeline include RX-1792, RX-5902, RX-3117, RX-8243, RX-0201, RX-0047, RX-21101 and RX-21202. In our complete report available for purchase the company is compared to: Gelstat Corp., Mannkind Corporation and Novelos Therapeutics, Inc..

Rexahn Pharmaceuticals Inc.

Stock Data:

Recent Stock Performance:

Current Price (2/10/2012): .60
(Figures in U.S. Dollars)

1 Week	-1.0%	13 Weeks	42.4%

4 Weeks	1.4%	52 Weeks	-65.6%

Rexahn Pharmaceuticals Inc. Key Data:

Ticker:	RNN	Country:	UNITED STATES

Exchanges:	ASE	Major Industry:	Drugs, Cosmetics & Health Care

		Sub Industry:	Ethical Drug Manufacturers

2010 Sales	75,000 (Year Ending Jan 2011).	Employees:	14

Currency:	U.S. Dollars	Market Cap:	57,016,702

Fiscal Yr Ends:	December	Shares Outstanding:	95,345,656

Share Type:	Common	Closely Held Shares:	14,835,146

Feedback | Terms and Conditions | Privacy Policy | Site Index

CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.